BLRX

Business Context and Reporting Period

Company: BioLineRx Ltd. (Nasdaq: BLRX)
Filing Type: Annual Report on Form 20-F
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: BioLineRx is a biopharmaceutical company focused on oncology and rare diseases. Its primary asset is APHEXDA (motixafortide), approved by the FDA in September 2023 for stem cell mobilization in multiple myeloma. In November 2024, the Company out-licensed global rights (excluding Asia and solid tumors) to Ayrmid Pharma Ltd., shutting down its independent U.S. commercial operations to refocus on development in Israel. The Company retains rights to develop motixafortide for solid tumors.

Key Financial Metrics

Note: The 2024 revenue increase was driven by upfront payments from the Ayrmid and Gloria license agreements and product sales of APHEXDA prior to the November 2024 transition.

Material Changes vs. Prior Period

• Revenue Surge: Revenues increased 502% to $28.9 million, primarily due to $15.0 million recognized from the Gloria License Agreement (Asia) and $7.8 million from the Ayrmid License Agreement (Global ex-Asia), plus $6.0 million in product sales.
• Reduced Operating Loss: Net loss narrowed significantly to $9.2 million from $60.6 million in 2023. This improvement was driven by reduced R&D expenses ($9.2M vs $12.5M) and lower sales/marketing costs ($23.6M vs $25.3M) following the shutdown of U.S. commercial operations.
• Non-Operating Income: The Company recorded $18.4 million in non-operating income, largely due to favorable fair-value adjustments on warrant liabilities, compared to $10.8 million in non-operating expenses in 2023.
• Debt Restructuring: In November 2024, the Company amended its loan agreement with BlackRock, repaying $16.5 million in partial settlement and restructuring the remaining balance over three years. This resulted in a one-time $4.0 million interest expense charge.
• Impairment: Recorded a $1.0 million impairment charge related to remaining rights for motixafortide in solid tumor indications, compared to a $6.7 million impairment in 2023 related to the AGI-134 asset.

Guidance, Outlook, and Risks

• Going Concern: Management and the independent auditor have expressed substantial doubt about the Company's ability to continue as a going concern due to recurring losses and negative cash flows. However, management believes current resources, including proceeds from a January 2025 offering ($8.9 million net), will fund operations through the second half of 2026.
• Strategic Shift: The Company has transitioned from a commercialization model to a development-focused model in Israel, relying on royalties and milestones from Ayrmid and Gloria for future revenue.
• Key Risks:
  • Liquidity: Dependence on future milestone payments and potential need for additional financing.
  • Partner Performance: Gloria is currently late on a $2.4 million milestone payment, and planned studies in China are delayed.
  • Legal: An ongoing arbitration with Biokine Therapeutics Ltd. regarding a $6.5 million claim for alleged breach of contract.
  • Geopolitical: Operations are based in Israel; ongoing regional conflict poses risks to operations and personnel, though no material impact has been reported to date.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $19.6 million cash balance plus the $8.9 million January 2025 proceeds against the projected burn rate through mid-2026.
• Partner Payments: Monitor the status of the $2.4 million overdue payment from Gloria and the initiation of delayed clinical studies in China.
• Debt Covenants: Review the amended BlackRock loan terms, specifically the $4 million minimum cash balance covenant and the requirement to use 10% of future milestones for debt repayment.
• Legal Exposure: Track the outcome of the arbitration with Biokine regarding the $6.5 million claim.
• ADS Ratio: Note the January 2025 reverse split (1 ADS = 600 ordinary shares) which adjusted historical share counts and prices retroactively.